Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.57 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.53 |
| ▸ | KDR | P35968 | 3/20 | 0.53 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.53 |
| ▸ | KIT | P10721 | 3/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24009188 | 0.83 | IRAK4 (0.47) | IRAK4EPHA2KDREPHB4PDGFRA | |
| SCHEMBL4400367 | 0.79 | PDGFRB (0.72) | PDGFRAPDGFRB | |
| SCHEMBL5501482 | 0.78 | IRAK4 (0.49) | IRAK4 | |
| SCHEMBL15580123 | 0.76 | KDR (0.56) | IRAK4EPHA2KDREPHB4KIT | |
| SCHEMBL5824748 | 0.76 | PDGFRA (0.83) | KDRPDGFRAKITFLT3MET | |
| SCHEMBL5824898 | 0.76 | PDGFRA (0.83) | KDRPDGFRAKITFLT3MET | |
| SCHEMBL5508687 | 0.75 | IRAK4 (0.49) | IRAK4 | |
| SCHEMBL17137654 | 0.74 | IRAK4 (0.65) | IRAK4 | |
| SCHEMBL30497408 | 0.74 | IRAK4 (0.65) | IRAK4 | |
| SCHEMBL5825712 | 0.74 | PDGFRA (0.59) | KDRPDGFRAKITFLT3MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | ENPP1, ENPP3, SMPD1 | IRAK4 2820/4885EPHA2 3521/4885KDR 3654/4885 |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | ENPP1, ENPP3, SMPD1 | IRAK4 2820/4885EPHA2 3521/4885KDR 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.